In the past two decades public debate about the risks, benefits, and safety associated with drugs has intensified. Public disputes over risks are brought to court when individuals seek compensation for health problems attributed to a pharmaceutical product. The issue reaches legislatures and regulatory agencies when consumer advocates seek to influence the standards of drug usage. Front-page news tends to focus on accidents or other risk events with drugs. Drug risk and drug safety have become an important political issue. Drug regulat- ory agencies have been instituted, and their responsibility has increased. The approval to market a drug is dependent on a set of sophisticated studies executed according to strict protocols and scientifically defined criteria. Drug surveillance activities have gained recognition, and reporting systems to identify drug safety problems have been strengthened. The understanding and management of drug safety is, nonetheless, beset by doubts, disagreements, and disputes. Conflict occurs over the significance of risk, the adequacy of evidence, the methodologies used to evaluate and measure risk, the standards that guide regulation, and the optimal means of communicating risk information to the public.
"Sinopsis" puede pertenecer a otra edición de este libro.
In the past two decades public debate about the risks, benefits, and safety associated with drugs has intensified. Public disputes over risks are brought to court when individuals seek compensation for health problems attributed to a pharmaceutical product. The issue reaches legislatures and regulatory agencies when consumer advocates seek to influence the standards of drug usage. Front-page news tends to focus on accidents or other risk events with drugs. Drug risk and drug safety have become an important political issue. Drug regulat ory agencies have been instituted, and their responsibility has increased. The approval to market a drug is dependent on a set of sophisticated studies executed according to strict protocols and scientifically defined criteria. Drug surveillance activities have gained recognition, and reporting systems to identify drug safety problems have been strengthened. The understanding and management of drug safety is, nonetheless, beset by doubts, disagreements, and disputes. Conflict occurs over the significance of risk, the adequacy of evidence, the methodologies used to evaluate and measure risk, the standards that guide regulation, and the optimal means of communicating risk information to the public.
This book represents a collaborative effort by academic experts, members of the pharmaceutical industry, international organizations, and public spokesmen to explore the problems associated with drug risk and drug safety. In an international conference, representatives from 10 countries discussed pharmacology, epidemiology, risk evaluation, regulatory standards, and public communication. Specific topics dealt with include the risk/benefit relationship, biostatistical data interpretation, consumer perception, and proposals for multidisciplinary and international efforts to address challenges in drug safety management.
"Sobre este título" puede pertenecer a otra edición de este libro.
Librería: Reader's Corner, Inc., Raleigh, NC, Estados Unidos de America
Cloth. Condición: Fine. No Jacket. First Edition. This is a fine, unmarked, hardcover first edition copy, blue cloth binding, no DJ. Nº de ref. del artículo: 050540
Cantidad disponible: 1 disponibles
Librería: NEPO UG, Rüsselsheim am Main, Alemania
Gebundene Ausgabe. Condición: Sehr gut. 216 Seiten ex LIbrary 'Book aus einer wissenschaftlichen Bibliothek Sprache: Englisch Gewicht in Gramm: 550. Nº de ref. del artículo: 251151
Cantidad disponible: 1 disponibles
Librería: AMAHOFF- Bookstores, Roßtal, Alemania
Condición: Sehr gut. Auflage: 1. 240 Seiten Sehr gutes Exemplar 55 9783540505341 Sprache: Englisch Gewicht in Gramm: 626 0,0 x 0,0 x 0,0 cm, Gebundene Ausgabe. Nº de ref. del artículo: 103561
Cantidad disponible: 1 disponibles